| Bioactivity | Itepekimab (REGN-3500) is a monoclonal antibody of IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. Itepekimab has potential application in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD)[1][2][3][4]. |
| Name | Itepekimab |
| CAS | 2226742-52-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. [2]. Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298. [3]. Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395. [4]. Scott JB, et al. Novel treatments for pediatric atopic dermatitis. Curr Opin Pediatr. 2021 Aug 1;33(4):392-401. |